异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响

doi:10.3969/j.issn.1671-7171.2020.02.012

摘要
图/表
参考文献(11)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】探究异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响。【方法】选择2014年8月至2017年5月在本院接受治疗的180例原发性肝癌患者作为研究对象。根据肝动脉化疗栓塞(TACE)术后保肝方案不同,分为A组(还原型谷胱甘肽＋异甘草酸镁注射液)和B组(异甘草酸镁+丁二磺酸腺苷蛋氨酸)。比较两组患者治疗后血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、直接胆红素(DBIL)和总胆红素(TBIL)水平。观察两组患者治疗后不良反应发生情况。分析影响原发性肝癌患者预后的相关因素。【结果】治疗后,两组患者血清ALT、AST、DBIL和TBIL水平均较治疗前升高,差异有统计学意义(P<0.05)。B组患者治疗后血清ALT、AST、DBIL和TBIL水平均低于A组,差异有统计学意义(P<0.05)。A组患者胃肠道反应、白细胞减少、血红蛋白减少和血小板减少的发生率分别为26.44%、25.29%、20.69%和2.30%,B组患者胃肠道反应、白细胞减少、血红蛋白减少和血小板减少的发生率分别为24.73%、20.43%、16.13%和2.15%。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。A组患者平均生存时间为27.40(95%CI:25.22～29.59)个月,B组患者平均生存时间为30.27(95%CI:28.40～32.14)个月。两组患者3年生存时间比较,差异有统计学意义(P<0.05)。Cox单因素及多因素分析结果显示肿瘤数目、血管侵犯及保肝方案与原发性肝癌患者预后密切相关。【结论】异甘草酸镁联合丁二磺酸腺苷蛋氨酸保肝治疗能改善原发性肝癌患者TACE治疗后肝功能及其预后,值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈宏伟
	杨孙虎

关键词 ：肝肿瘤, 栓塞,治疗性, 甘草酸/药理学

Abstract：【Objective】To explore the effect of magnesium isoglycate combined with ademetionine succinate on liver function and prognosis after interventional therapy for primary liver cancer.【Methods】One hundred and eighty patients with primary liver cancer who were treated in our hospital from August 2014 to may 2017 were selected as the study objects. According to the different schemes of liver protection after TACE, it was divided into two groups: group A (reduced glutathione + magnesium isoglycate injection) and group B (magnesium isoglycate + adenosylmethionine succinate). Serum ALT, AST, DBIL and TBIL levels were compared between the two groups. The adverse reactions of the two groups were observed to analyze the prognostic factors of patients with primary liver cancer.【Results】After treatment, the levels of ALT, AST, DBIL and TBIL in the two groups were significantly higher than those before treatment (P<0.05). The levels of ALT, AST, DBIL and TBIL in the group B were lower than those in the group A (P<0.05). The incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group A were 26.44%, 25.29%, 20.69% and 2.30% respectively; the incidence of gastrointestinal reaction, leucopenia, hemoglobin reduction and thrombocytopenia in the group B were 24.73%, 20.43%, 16.13% and 2.15%, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The mean survival time of the group A was 27.40 (95% CI: 25.22~29.59) months, and that of the group B was 30.27 (95% CI: 28.40~32.14) months.There was significant difference between the two groups in the 3a survival time (P<0.05).Cox single factor and multi factor analysis showed that tumor number, vascular invasion and liver protection were closely related to the prognosis of patients with primary liver cancer.【Conclusion】Magnesium isoglycate combined with ademetionine succinate can improve the liver function and prognosis of patients with primary liver cancer after TACE treatment, which is worthy of clinical promotion.

Key words： Liver Neoplasms Embolization,Therapeutic Glycyrrhizin/MT

收稿日期: 2019-05-19

PACS:

R735.7

通讯作者: E-mail:876206438@qq.com

引用本文:

陈宏伟, 杨孙虎. 异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响[J]. 医学临床研究, 2020, 37(2): 199-202.
CHEN Hong-wei, YANG Sun-hu. Effect of Magnesium Isoglycate Combined with Ademetionine Succinate on Liver Function and Prognosis after Interventional Therapy for Primary Liver Cancer. JOURNAL OF CLINICAL RESEARCH, 2020, 37(2): 199-202.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.02.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I2/199

[1] Wang Z, Zhang G, Wu J,et al. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect[J].Drug Discov Ther,2013,7(4):137-143.
[2] Seki A, Kobayashi K, Narumiya S. Transcatheter Arterial Chemoembolization with Epirubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience[J].Cardiovasc Intervent Radiol,2011,34(3):557-565.
[3] 高慧涛,王美玲,陈小冰,等.复方甘草酸苷联合舒肝宁对原发性肝癌肝动脉灌注化疗栓塞术后保肝作用的临床观察[J].中国药物与临床,2013,13(11):1487-1488.
[4] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华消化外科杂志,2017,16(7):635-647.
[5] 何强.苦参素辅助治疗乙型病毒性肝炎相关原发性肝癌的临床观察[J].中国医院药学杂志,2014,34(22):1930-1933.
[6] Chen ZH, Zhang XP, Cai XR, et al. The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy[J].J Cancer,2018,9(19):3467-3478.
[7] Yu JI, Choi GS, Lim DH, et al. Treatment of Na ve HCC combined with segmental or subsegmental portal vein tumor thrombosis:liver resection versus TACE followed by radiotherapy[J].Anticancer Res,2018,38(8):4919-4925.
[8] Chen J, Zhang Y, Cai H, et al. Comparison of the effects of postoperative prophylactic transcatheter arterial chemoembolization (TACE) and transhepatic arterial infusion (TAI) after hepatectomy for primary liver cancer[J].J BUON,2018,23(3):629-634.
[9] 中华医学会感染病学分会,肝脏炎症及其防治专家共识专家委员会.肝脏炎症及其防治专家共识[J].中华肝脏病杂志,2014,22(2):94-103.
[10] 广东省抗癌协会肝癌专业委员会.肝癌多学科综合治疗团队建立--广东专家共识(1)[J].临床肝胆病杂志,2014,34(11):1112-1115.
[11] 武中林,吴勇超,杨超,等.原发性肝癌经导管肝动脉化疗栓塞术后应用不同保肝方案的效果比较研究[J].中国全科医学,2017,20(23):2862-2867,2874.